Glox Therapeutics Wins £3M Cystic Fibrosis Funding Glox Therapeutics, a leader in developing precision antibiotic therapies using naturally occurring bacteriocins, has announced it has been awarded a portion of the £3 million Collaborative Discovery Programme (CDP) funding from the Cystic…
Know Labs, Inc. (NYSE American: KNW), a trailblazer in the development and application of radio frequency dielectric spectroscopy (RFDS), is excited to unveil the creation of its new business unit, Know Labs Technology Licensing (KTL). Drawing inspiration from the successful…
Heart & Kidney Health Screening Available for Free in Seattle, Jan 22-24 Care Access, a health and research company, is offering its Heart & Kidney Health Screening initiative to residents of Seattle. This initiative aims to raise awareness and provide…
Appoints Mark R. Bamforth as CEO to Drive Growth at Kincell Bio Kincell Bio, a leader in the cell therapy development and manufacturing sector, appoints Mark R. Bamforth as Chief Executive Officer (CEO), effective immediately. Mark, who has served as…
Translation App for Medical Aesthetics Launched by SBC Medical, Boosting Clinic Initiative Shonan Beauty Clinic (SBC), supported by SBC Medical Group Holdings Incorporated (Nasdaq: SBC), has launched an innovative translation app tailored specifically for the medical aesthetics industry. This new…
Brain-Computer Interface Development: Motif Neurotech Wins UK Award Motif Neurotech, a neurotechnology company based in Houston, has been awarded a multimillion-dollar grant by the UK’s Advanced Research and Invention Agency (ARIA). The funding will support the company’s development of a…
Agreement Between InnoCare, KeyMed, and Prolium for CD20xCD3 Bispecific Antibody License InnoCare Pharma (HKEX: 09969; SSE: 688428) and KeyMed Biosciences (HKEX: 02162) have announced the signing of an exclusive license agreement with Prolium Bioscience (Prolium) for the global development and…
Breast Cancer: DATROWAY® Approved in U.S. for Metastatic HR Positive, HER2 Negative Type DATROWAY® (datopotamab deruxtecan-dlnk), an innovative TROP2-directed antibody-drug conjugate (ADC), has been approved by the U.S. Food and Drug Administration (FDA) for treating adult patients with unresectable or…
Arrowhead Announces FDA NDA Acceptance of Plozasiran Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for investigational plozasiran as a treatment for familial chylomicronemia syndrome (FCS),…
ImmunoPrecise Antibodies Realigns Pipeline with AI and First-Principles Innovation ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today unveiled its AI-powered pipeline, designed to revolutionize therapeutic development. This new system combines cutting-edge artificial intelligence with first-principles thinking, creating the BioStrand pipeline. By reimagining…